Reply to: Comparator choices in pharmacoepidemiology studies of Alzheimer's disease
Pengyue Zhang1, Yuan Hou2, Chien-Wei Chiang3
1Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, USA.
No abstract available in PubMed .
More Related Videos
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Related Concept Videos
Alzheimer's Disease: Treatment
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Comparing the Survival Analysis of Two or More Groups
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
